发明名称 PREPARATION, COMPRISING IRON (III) COMPLEX COMPOUNDS AND REDOX-ACTIVE SUBSTANCES
摘要 <p>#CMT# #/CMT# Preparation (C1) comprises one or more iron (III)-complex compounds, which exhibit a pH of 7 and a redox potential of -324 mVs to -750 mVs towards normal hydrogen electrode, and one or more redox-active substance, where the carbohydrate e.g. dextrin, oxidized or hydrated dextrin, pullulan, oligomer and/or hydrated pullulan, and the redox-active substances are ascorbic acid, vitamin E, cystein, quercetin, rutin, flavone, flavonoid, hydroquinone comprising physiologically compatible phenol/polyphenol, and glutathione, preferably ascorbic acid. #CMT#ACTIVITY : #/CMT# Antianemic; Antiinflammatory; Gastrointestinal-Gen; Antiulcer; Immunostimulant; Muscular-Gen; Cerebroprotective. The ability of the preparation to treat iron deficiency was tested in human. The result showed after the administration of the preparation the patient showed hemoglobin of >=130 g/l, transferring saturation of >=16% and ferritin of >=30 mu g/l, which decreases the iron deficiency. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# (C1) Is useful as a medicament for the treatment of iron deficiency conditions e.g. chronic inflammatory bowel disease, preferably Crohn or ulcer colitis or in pregnancy. (C1) Is useful to improve immune defense, to increase brainpower and/or to treat restless leg syndrome (all claimed). #CMT#ADVANTAGE : #/CMT# The medicament is released contemporarily or simultaneously with other redox-active substances (claimed). (C1) Exhibits improved bioavailability. (C1) Improves the hemoglobin content. #CMT#FOOD : #/CMT# Preferred Components: The redox active substance is present in the form of solution, preferably fruit juice. #CMT#INORGANIC CHEMISTRY : #/CMT# Preferred Components: The iron (III)-complex compound is iron-(III)-polymaltose complex compound with a molecular weight of 20000-500000 dalton. The iron (III)-complex compound is provided with an oxidation product of one or more maltodextrin. The iron (III)-complex compound is a water-soluble iron-carbohydrate complex, which is obtained from an aqueous iron (III)-salt solution and an aqueous solution of the oxidation product of one or more maltodextrin with an aqueous hypochlorite solution in an alkaline pH, where the maltodextrin is dextrose-equivalent of 5-37, the mixture of one or more maltodextrin of the dextrose-equivalent of the mixture is 5-37, and the dextrose equivalent of the maltose dextrin involved in single at the mixture is 2-40. The weight ratio of the iron (III)-complex compound and ascorbic acid is 1:0.05-1:20. #CMT#PHARMACEUTICALS : #/CMT# Preferred Components: (C1) Is in the form of kit, preferably in the form of a solution, where the iron (III)-complex compound and the redox active substance of (C1) are spatially separated. (C1) Is in the form of single-dose container. The pharmacological active component is present in the solution of iron (III) complex and/or redox active substance. Preferred Composition: (C1) Further comprises one or more pharmacological active components e.g. vitamins other than ascorbic acid, trace element, cofactor, mineral or nutrient substance. #CMT#ADMINISTRATION : #/CMT# Administration of (C1) is oral, in the form of tablet, granulate, capsule, fizzy-tablet, powder, shower granulates or sachet (claimed). The dosage of iron (III)-complex compound is 10-500 mg and redox active substance 50-300 mg. #CMT#EXAMPLE : #/CMT# Typical preparation in the form of tablet comprised of (in mg): beta -carotin (7.2), thiamine nitrate as vitamin B1 (2); vitamin B2 (1.8); pyridoxin hydrochloride as vitamin B6 (2.7); vitamin B12 (0.0026); ascorbic acid (95); vitamin D3 (10 mu g); vitamin E (12); biotin (0.1); calcium pantothenate (7.6); nicotinamide (20); folic acid (0.8); aqueous free copper sulfate (5); manganese chloride-tetrahydrate (11); zinc sulfate-monohydrate (52); aqueous free calcium hydrogen phosphate (439); magnesium oxide (166); iron (III)-polymaltose-complex (226); croscarmellose-sodium (41); aqueous free colloidal silicium oxide (7); magnesium stearate (6); microcrystalline cellulose (116); and Opadry (RTM: Filmogen) (50).</p>
申请公布号 IL190878(D0) 申请公布日期 2008.11.03
申请号 IL20080190878 申请日期 2008.04.15
申请人 VIFOR (INTERNATIONAL) AG. 发明人
分类号 A61K 主分类号 A61K
代理机构 代理人
主权项
地址